[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-soft-tissue-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-soft-tissue-sarcoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100532319","superiority-trial-evaluating-digitalized-information-media-for-patients-with-advanced-sarcomas-receiving-systemic-treatment-100532319",false,"NCT06211257","Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.","Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment for Metastatic or Locally Advanced Disease.","ePPS","Inclusion Criteria:\n\n* Sarcomas of soft tissues or viscera ;\n* Inoperable metastatic or locally advanced disease ;\n* Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ;\n* Patient covered by French social security ;\n* Written, signed, informed consent ;\n\nExclusion Criteria:\n\n* Prior inclusion in ePPS trial for a prior systemic treatment ;\n* Poor understanding of French ;\n* Difficulty accessing a computer ;\n* Pregnant or nursing woman ;\n* Person deprived of liberty or under guardianship ;\n* Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.","ALL","18 Years",{"count":20,"type":21},377,"ESTIMATED","INTERVENTIONAL",[24],"NA","ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information\u002FPCP for patients with advanced sarcomas receiving systemic treatment.\n\nParticipants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone.\n\nAll patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.",[27,28],"Sarcoma Metastatic","Locally Advanced Soft Tissue Sarcoma",[30,31,32,33,34],"Sarcoma","Advanced","Dematerialised","Care","Plan","RECRUITING","2026-03-16",{"date":38,"type":39},"2026-03-18","ACTUAL",{"date":41,"type":39},"2024-05-29",{"date":43,"type":21},"2030-04",{"name":45,"class":46},"Centre Oscar Lambret","OTHER",11,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100604986","phase-2-a-prospective-single-arm-multicenter-exploratory-clinical-study-of-anlotinib-combined-with-bempegaldesleukin-and-conventional-chemoradiotherapy-for-the-treatment-of-unresectable-locally-advanced-or-metastatic-soft-tissue-sarcoma-100604986","NCT07156643","A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.","Inclusion Criteria:\n\n1. Age: 18 to 80 years.\n2. Diagnosis: Pathologically confirmed, investigator-assessed metastatic or unresectable locally advanced soft tissue sarcoma, classified as Stage IV according to the AJCC (8th Edition) staging system. Eligible histologic subtypes per the WHO (2013) classification include anthracycline-insensitive types, primarily: myxoid\u002Fround cell liposarcoma, Grade 1 dedifferentiated liposarcoma, clear cell sarcoma, endometrial stromal sarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma\u002Fprimitive neuroectodermal tumor (PNET), embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, gastrointestinal stromal tumor (GIST), etc. Eligibility of other rare soft tissue sarcoma subtypes will be determined by the investigator.\n3. Measurable Disease: At least one measurable or evaluable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n4. Life Expectancy: ≥ 3 months.\n5. Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n6. Adequate Organ Function: Must meet the following criteria within 7 days prior to treatment initiation:1）Hematological (without transfusion or use of growth factors within 14 days):Hemoglobin (Hb) ≥ 90 g\u002FL,Absolute Neutrophil Count (ANC) ≥1.5 × 10⁹\u002FL,Platelet count (PLT) ≥75×10⁹\u002FL;Biochemical:Total Bilirubin (TBIL) ≤1.5 × Upper Limit of Normal (ULN),Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)≤ 2.5× ULN,Serum Creatinine (Cr)≤ 1.5 × ULN or Creatinine Clearance (CrCl) ≥ 60 mL\u002Fmin,Urinalysis: Urine protein\\\u003C 2+ and 24-hour urine protein quantification must show protein≤1 g;Coagulation: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN;Cardiac Function: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as assessed by Doppler ultrasound;Thyroid Function: Thyroid-Stimulating Hormone (TSH) ≤ 2.0 × ULN; if abnormal, T3 and T4 levels must be within normal limits for enrollment.\n7. Contraception: Women of childbearing potential must have used reliable contraception, have a negative pregnancy test (serum or urine) within 7 days prior to enrollment, and be willing to use adequate contraception during the trial and for 8 weeks after the last dose of the study drug. Men must agree to use adequate contraception or be surgically sterile during the trial and for 8 weeks after the last dose.\n8. Treatment Plan and Consent: The investigator plans to administer the combined chemoradiotherapy and targeted immunotherapy regimen, and the patient has provided written informed consent.\n\nExclusion Criteria:\n\n1. Prior treatment with PD-1\u002FPD-L1\u002FCTLA-4 antibodies, radiotherapy, or any targeted therapy.\n2. Tumor invasion of major blood vessels.\n3. Active, known, or suspected autoimmune disease.\n4. Known history of primary immunodeficiency.\n5. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n6. Pregnant or lactating female patients.\n7. Uncontrolled concurrent illnesses, including but not limited to:HIV infection (HIV antibody positive).Active or clinically poorly controlled severe infection.Active hepatitis.Evidence of severe or uncontrolled systemic diseases (e.g., severe psychiatric, neurological, epileptic, or dementia disorders; unstable or decompensated respiratory, cardiovascular, hepatic, or renal diseases; uncontrolled hypertension \\[defined as ≥ Grade 2 hypertension per CTCAE despite medical therapy\\]).Active bleeding or newly diagnosed thrombotic disease requiring therapeutic anticoagulation, or bleeding tendency; coagulation abnormalities (INR \\> 1.5 × ULN, APTT \\> 1.5 × ULN).\n8. Current participation in another drug clinical trial.\n9. Any other condition deemed by the investigator to make the patient unsuitable for inclusion.","80 Years",{"count":56,"type":21},46,[58],"PHASE2","This study employs a multicenter, single-arm trial design. Participants will receive a treatment regimen consisting of \"anlotinib plus bempegaldesleukin concurrent with radiotherapy,\" followed by a maintenance therapy phase of \"anlotinib plus bempegaldesleukin concurrent with chemotherapy.\" The study aims to evaluate the clinical efficacy and safety of anlotinib in combination with bempegaldesleukin and conventional chemoradiotherapy for the treatment of unresectable locally advanced or metastatic soft tissue sarcoma.",[28],"NOT_YET_RECRUITING","2025-08-28",{"date":64,"type":39},"2025-09-05",{"date":66,"type":21},"2025-10-01",{"date":68,"type":21},"2030-10-01",{"name":70,"class":46},"The First Affiliated Hospital with Nanjing Medical University",1]